Comparison of the effect of triple standard treatment of helicobacter pylori versus combination therapy of triple standard treatment with probiotic (Femilact) on treatment of patients with helicobacter pylori infection

Comparison of the effect of triple standard treatment of helicobacter pylori versus combination therapy of triple standard treatment with probiotic (Femilact) on treatment of patients with helicobacter pylori infection: A randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201612319014N140

Enrollment

142

Registered

2017-01-09

Start date

2017-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: Intervention group: Oral Amoxicillin 1 gr twice a day, Oral Clarithromycin 500 mg twice a day, Pantoprazole tablet 40 mg twice a day, and Femilact Probiotic capsule 500 mg twice a day

Treatment - Drugs

Intervention group: Oral Amoxicillin 1 gr twice a day, Oral Clarithromycin 500 mg twice a day, Pantoprazole tablet 40 mg twice a day, and Femilact Probiotic capsule 500 mg twice a day for 14 days.

Control group: Oral Amoxicillin 1 gr twice a day, Oral Clarithromycin 500 mg twice a day, and Pantoprazole tablet 40 mg twice a day for 14 days

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: affected with helicobacter pylori infection; age of 18 to 75 years. Exclusion criteria: Stomach cancer; renal or liver failure; pregnancy or breastfeeding; history of stomach surgery; history of treatment failure of helicobacter pylori infection

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Microbial load. Timepoint: 8 weeks after treatment. Method of measurement: through respiratory urease test.	—

Secondary

Measure	Time frame
Probable side effects. Timepoint: 8 weeks after treatment. Method of measurement: through question and physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ali Pouladrag

Shahid Beheshti Hospital

alipouladrag@gmail.com+98 81 3838 0283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026